(Q34615891)

3 August 2017

1 reference

title

Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci (English)

1 reference

3 August 2017

author name string

Irma A J M Bakker-Woudenberg

series ordinal

1

1 reference

3 August 2017

publication date

1 April 2002

1 reference

International Journal of Antimicrobial Agents

3 August 2017

published in

1 reference

3 August 2017

volume

19

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

299-311

1 reference

The past, present, and future uses of liposomes in treating infectious diseases

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomal drug formulations. Rationale for development and what we can expect for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposome disposition in vivo. III. Dose and vesicle-size effects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes in the treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Biopharmaceutical aspects of lipid formulations of amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Lipid-based amphotericin B formulations: from animals to man.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Lipid-based antifungal agents: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Lipid-based amphotericin B: a review of the last 10 years of use.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Trends and developments in liposome drug delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Large unilamellar liposomes with low uptake into the reticuloendothelial system

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Targeting of liposomes to tumor cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

The role of surface charge and hydrophilic groups on liposome clearance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes for the sustained drug release in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Novel applications of liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Controlling liposome blood clearance by surface-grafted polymers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Pharmacokinetics of stealth versus conventional liposomes: effect of dose

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Thermodynamic analysis of the permeability of biological membranes to non-electrolytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes for scintigraphic detection of infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Radiolabeled liposomes for scintigraphic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Enhanced encapsulation of amphotericin B into liposomes by complex formation with polyethylene glycol derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Molecular localization and state of amphotericin B in PEG liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

The uptake mechanisms of inflammation- and infection-localizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Scintigraphic imaging using 99m Tc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Dual radiolabeled liposomes: biodistribution studies and localization of focal sites of infection in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Technetium-99m labelled liposomes to image experimental arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900021-3

7 January 2021

10.1016/S0924-8579(02)00021-3

Identifiers

DOI

1 reference

3 August 2017

1 reference